Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose statin therapy in late-onset myasthenia gravis
ChiCTR2000037904Phase 4Not yet recruiting
- Sponsor
- Shandong Provincial Qianfoshan Hospital
- Start
- Sep 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ulinastatin in myasthenia gravis (MG) and atherosclerotic disease, sponsored by Shandong Provincial Qianfoshan Hospital. Primary endpoints: Activity of Daily Living (ADL) scale at day 56 and Quantitative Myasthenia Gravis (QMG) score at day 56. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
ulinastatin
03
Conditions
myasthenia gravis (MG)atherosclerotic disease
Beyond the preview
Go deeper on ChiCTR2000037904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037904.